Overview

Safety and Efficacy of Ranibizumab in Japanese Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration

Status:
Completed

Trial end date:
2009-01-01

Target enrollment:

Participant gender:

Summary

Open-label Multicenter, Phase I/II Study comprising three phases (single dose, multiple dose and extension phase), Assessing the Safety and Efficacy of Ranibizumab (RFB002) in Japanese Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD).

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Novartis

Treatments:

Ranibizumab